Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REEDEM-1: BCX9930 monotherapy vs continued C5 inhibitor therapy in PNH with inadequate response
jRCT2051210179Active, not recruiting
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of vimircopan in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Change from baseline in hemoglobin. Started Jan 2022; status: active, not recruiting.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2051210179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210179.